Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 19, 2009

Ligon Discovery Raises $1M

  • Ligon Discovery, which uses small molecule microarray technology to find drugs against high-value targets, has raised $1 million in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets.

    Patrick Kleyn, Ph.D., Angela Koehler, Ph.D., and Benjamin Ebert, M.D., Ph.D., founded Ligon Discovery with an exclusive license to technology invented at Harvard University. According to Dr. Kleyn, “Ligon’s technology has already been used to discover drug compounds against high-value targets including protein kinases, histone deacetylases, extracellular growth factors, and transcription factors.”

    Ligon Discovery’s high-throughput microarray “chip” reportedly transforms the speed of the drug discovery process and expands the scope of new drug prospecting to include previously intractable targets.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »